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Abstract The ¢z4 subunit of the neuronal nicotinic acetylcholine 
receptor is the first gene shown to be involved in a human 
idiopathic epileptic disease. A missense mutation, leading to the 
replacement of serine 248 by phenylalanine in the second 
transmembrane segment, had been detected in patients with 
autosomal dominant nocturnal frontal lobe epilepsy. The proper- 
ties of the wild type receptor composed of ~4 and ~2 subunits and 
the mutant receptor where ¢z4 subunits carried the mutation at 
serine 248 were compared by means of cDNA manipulation and 
expression in Xenopus oocytes. The mutant receptor exhibited 
faster desensitization upon activation by acetylcholine and 
recovery from the desensitized state was much slower than in 
the wild type receptor. We conclude that the reported mutation 
causes seizures via a diminution of the activity of the ¢x4[~2 
neuronal nicotinic acetylcholine receptor. 
l~y  words. Acetylcholine receptor; Ion channel; 
E ectrophysiology; Complementary DNA; Xenopus laevis; 
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I Introduction 
The neuronal nicotinic acetylcholine r ceptor (nAChR be- 
kngs to the family of ligand-gated ion channels [1]. Several 
m:uronal a and 13 subunits have been cloned that give rise to 
receptors with distinct electrophysiological and pharmacologi- 
c, 1 features [1,2]. Among these, recombinant e~7, c~8 and c~9 
st bunits can form functional homo-oligomers [3] whereas 
oher  c~ subunits may coassemble with at least one type of 13 
s~ bunit ([4], for review). The predominant nAChR subtype in 
r~ t and chicken brain contains c~4 and 132 subunits and recent 
fi idings suggest hat c~5 subunits may also participate in the 
c,,nstitution of this receptor subtype [5,6]. 
In analogy to the pentameric nAChR of skeletal muscle it is 
a sumed that neuronal receptors are formed by five subunits 
o '  as yet unknown stoichiometry. Each subunit folds with 
f iur putative transmembrane segments and the so-called 
q M2 segments form the walls of the channel pore [7-9]. 
1. pon binding of ACh the pore-lining segments reorientate 
t, allow cations to flow [10]. During prolonged exposure to 
A Ch or repeated application of ACh at high frequency the 
n ~.ChRs convert o a desensitized configuration which is un- 
r, sponsive to added ACh, has a higher affinity to agonists and 
iv more stable than the active states [11-13]. 
The gene encoding the c~4 subunit of the human neuronal 
n~,ChR (CHRNA4) has been mapped to chromosome 
2LIq13.2-q13.3 between the markers D20S20 and D20S24 
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[14]. Another marker, D20S19, has been localized adjacent 
to D20S20 and D20S24 and is tightly linked to the three 
brain-specific phenotypes benign familial neonatal convulsions 
(BFNC) [15,16], low-voltage EEG (LVEEG) [17] and autoso- 
mal dominant nocturnal frontal lobe epilepsy (ADNFLE) 
[18]. ADNFLE is a partial epilepsy which typically begins in 
childhood and leads to clusters of brief seizures during light 
sleep or drowsing [19]. Recently, a mutation in the CHRNA4 
gene was found in affected members of a large Australian 
pedigree in which the ADNFLE gene has been shown to be 
linked to chromosome 20q13.2-q13.3 [20]. A C to T transition 
in amino acid position 248 was detected leading to the re- 
placement of serine by phenylalanine in the sixth residue of 
the second transmembrane s gment (Fig. 1). The mutation 
was found in all clinically affected pedigree members, but 
not in 333 control individuals. 
Interestingly, the mutated residue is located at a position 
termed the inner polar site (IPS) [21], which has been highly 
conserved not only during the evolution of all the agonist- 
binding nAChR subunits in different species but also in the 
GABAA and 5-HT3 receptor. In some receptor subunits erine 
is substituted by the polar threonine. Furthermore, Ser 248 at 
position 6' is located next to the most conserved residue in the 
TM2 sequence - Leu TM - separated only by one turn within a 
putative c~-helical arrangement. According to the model pro- 
posed by Unwin [9], this Leu TM together with the leucine 
residues at homologous positions of the other subunits creates 
a tight hydrophobic ring at the most constricted part of the 
closed pore. Ser 248 would be positioned immediately beneath 
this gate of the closed receptor in the lower part of the TM2 
segment where small residues with hydroxyl groups alternate 
with bulky hydrophobic side-chains. A number of studies up- 
port the view that Ser 24s is facing the pore in the mouse 
muscle and Torpedo electric organ nAChR [8]. The functional 
importance of the serine and threonine, respectively, at the 
sixth position of the TM2 segment has been emphasized based 
on experiments with site-directed mutagenesis in the cd sub- 
unit of the mouse muscle nAChR and the c~7 subunit of the 
chicken neuronal receptor. These results suggest hat this po- 
sition affects the affinity to ACh [22,23], desensitization prop- 
erties [22], outward single-channel currents and concomitantly 
rectification [21]. 
Functional expression of recombinant neuronal nAChRs in 
Xenopus oocytes with characteristics similar to those of the 
native channels has been reported for several receptor sub- 
types [24,25]. In order to investigate the effects of the muta- 
tion Ser248phe on the electrophysiological features of the hu- 
man neuronal nAChR and to shed light on the mechanism by 
which it might cause seizures we introduced this amino acid 
0'114-5793196/$12.00 © 1996 Federation of European Biochemical Societies. All rights reserved. 
1HS0014-5793(96)01215-X  
92 
exchange into the cDNA for the human c~4 subunit. The 
mutated cDNA and the cDNA for the human 132 subunit 
were expressed in Xenopus oocytes to yield the mutant recep- 
tor, a4S248F132. Changes in dose-response r lations and de- 
sensitization kinetics in comparison to the wild type receptor, 
a4132, were assessed by voltage-clamp experiments. 
2.  Mater ia l s  and  methods  
2.1. Cloning of ~4 and 132 subunit cDNAs and mutagenesis 
The cDNA coding for the human neuronal nAChR 132 subunit [26] 
was obtained by amplification out of a human cerebral cortex cDNA 
pool (Human Brain Quick-Clone cDNA, Cerebral Cortex; Clonetech, 
Palo Alto, CA) by the use of primers flanking the translated region of 
the sequence (forward: GAGGCAGCGAGCTATGCCCA; reverse: 
TGGAGATGAGGAAGGGCCTCA). To get the 5' part of the c~4 
subunit cDNA a 5'-RACE was performed using the Human Fetal 
Brain Marathon-Ready cDNA (Clonetech) and an exon-5 specific 
primer (GGGCATGGTGTGCGTGCGTG) in combination with the 
adaptor primer AP2 supplied with the kit. The PCR product was used 
for a nested PCR with two c~4 subunit specific primers. The reverse 
primer was specific for sequences in exon 5 (CCACGATGACC- 
CACTCGCC) and the forward primer (CTAGATCTCGC- 
GAGGTGCGTG) bound to the 5' region flanking the start codon. 
PCR generated a fragment of 667 bp including a unique PstI site. The 
3' part was amplified employing the cDNA clone OS2-1-2 [14] and 
two a4 subunit specific primers (forward: GGCCGGA- 
CATCGTCTCTAC; reverse: GCCCCACAGAGTCCAGGGAG) 
yielding a cDNA fragment of 1622 bp containing the unique Pstl 
site as well. The two PCR fragments were ligated via the Pstl site 
and the complete ~4 cDNA was amplified out of the ligation reaction 
with two primers flanking the coding sequence (forward: 
CGAGGTGCGGGATCCATGGAGCTAGG; reverse: CCGCATG- 
GATCCTGGCCCCGTGCAC). With the help of these two primers 
BamHI sites were introduced at both ends of the ~4 cDNA and 
restriction of the BamHI sites yielded termini that were compatible 
with BgllI termini. Both the ct4 and the ~2 cDNA were cloned into 
pSPOoD [27], a derivative of pSP64T [28], using the BgllI restriction 
site. 
For the introduction of the mutation $248F into the a4 subunit 
cDNA a 618 bp fragment of exon 5 was amplified from the genomic 
DNA of an ADNFLE patient belonging to the chromosome 20-1inked 
Australian family [18] in which the mutation had been detected [20]. 
The PCR product included the TM2 segment with the C to T transi- 
tion in the sixth amino acid position and was exchanged for the 
corresponding fragment of the wild type cDNA in pSPOoD using 
single-cut DraIII and MunI sites. Plasmids containing the sequence 
of the mutant allele were identified by a PCR assay with one of the 
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primers carrying a one-base mismatch near the 3' end, creating a new 
HpaII restriction site in the wild type but not in the mutant allele [20]. 
The cloning constructs were sequenced according to the Sanger di- 
deoxy termination method (Sequenase Version 2.0 DNA Sequencing 
Kit; Amersham, Arlington Heights, IL) to verify that only the desired 
mutation was present. 
2.2. In vitro transcription and expression in ooo, tes 
Plasmid DNAs were linearized with SalI and transcribed in vitro 
with SP6 polymerase [29]. Xenopus laevis oocytes were injected [30,31] 
with 10-15 ng cRNA in approximately 50 nl water encoding the 
nAChR 132 subunit and the wild type or mutant c~4 subunit in a molar 
ratio 1:1 and incubated at 19 + I°C in OR2 medium (82.5 mM NaCI, 
2.5 mM KC1, 1.0 mM Na2HPO~, 5.0 mM HEPES, 1.0 mM MgCI2, 
1.0 mM CaCI2, 0.5 g/l PVP, pH 7.2 adjusted with NaOH) for 2 3 
days prior to electrophysiological recordings. The day after injection 
oocytes were treated with 1 mg/ml collagenase type I in OR2 for 30 
rain at room temperature and washed three times with OR2. After- 
wards the follicular cell layer was removed mechanically with forceps. 
2.3. Electrophysiological measurements 
Currents elicited in response to bath application of various acetyl- 
choline (ACh) concentrations to oocytes expressing either wild type or 
mutant nAChRs were measured with a standard two micro-electrode 
voltage-clamp at a holding potential of -70 inV. Electrodes were 
filled with 3 M KCI and had resistances of 0.1 7 M~. Oocytes were 
continuously perfused at room temperature with a modified frog 
Ringer solution (Mg2+-frog Ringer) without Ca 2+ (135 mM NaCI, 
5.4 mM KC1, 2.8 mM MgC12, 5 mM HEPES) to prevent activation 
of Ca2+-activated chloride channels. ACh was diluted in perfusion 
solution and applied for 5 s except where otherwise stated. Oocytes 
were washed for 3 5 min depending on ACh-concentration a d 
receptor type between exposures to ACh to minimize the desensitiz- 
ing effect of each preceding pulse on the following measurement. 
Dose-response data from each oocyte were normalized to the response 
to 30 ~tM ACh and fit to the equation 
0 - [1 + (ECs,,/[A])"] -1 
where 0 is the normalized current, ECs0 is the concentration f ACh 
required to obtain half-maximal current, [A] is the concentration of
ACh and n is the apparent Hill coefficient using a commercially avail- 
able software package (Igor, Wave Metrics, Oswego, OR). 
3.  Resu l t s  
3.1. The mutant receptor exhibits an accelerated esensitization 
Both the wild type c~4132 and the mutant a4S248F132 
nAChR produced functional channels when expressed in Xe- 
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Fig. 1. Amino acid sequences of TM2 segments and neighboring residues of different ligand-gated ion channels. At the top the position of the 
residues in the TM2 segment is given with the terminology following that of Miller [44] which assigns the number 1' to the residue at the puta- 
tive N-terminus of the TM2 sequence - the cytoplasmic end. At the bottom the corresponding amino acid position is shown referring to the 
numbering of the Torpedo (x subunit [45]. Residues marked in bold have been demonstrated to face the channel lumen in the mouse muscle re- 
ceptor by Akabas et al. [46]. Boxes are drawn around small polar or neutral residues that are repeated at every fourth position in the amino 
terminal half. Filled boxes indicate the IPS [21]. Amino acids that have been shown to influence desensitization by experiments with site-direc- 
ted mutagenesis are marked with superscript numbers indicating the corresponding reference. The serine that was substituted by phenyalanine 
in this study is highlighted by a circle, hc~4: human neuronal nAChR e~4 subunit; h132: human neuronal nAChR 132 subunit; mcd, Mus muscu- 
lus muscle nAChR ctl subunit; m131, Mus musculus muscle nAChR 131 subunit; my, Mus musculus muscle nAChR 7 subunit; m& Mus musculus 
muscle nAChR 8 subunit; ccc7, Gallus gallus neuronal nAChR c~7 subunit: m5-HT3: Mus musculus 5-HT:~ receptor; dGABA, Drosophila mela- 
nogaster GABA receptor. 
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F i .  2. Effect of the mutation on desensitization ki etics. A: Macro- 
so pic currents elicited by twice bath application of 1 gM ACh for 
1 nin to oocytes with wild type or ~4S248F[32 nAChRs. The inter- 
va between the two pulses was 2 min. Note the marked increase of 
de,,ensitization for the o~4S248F[32 nAChR. Recordings performed in 
se',eral oocytes displayed identical features. B: Rate constants (s ~) 
of current inactivation for wild type (O) and a4S248F[32 (©) 
nAChRs were estimated by a monoexponential fit to the time 
co lrse for the reduction of the current amplitude during l min ap- 
plication of 0.3, 1 and 3 gM ACh concentrations and plotted 
agtinst the ACh concentration. Each point represents the 
m, an+S.D, obtained in 2 (wild type) and 9 (mutant) cells from 
m~,re than one batch of oocytes. 
m,ous oocytes. Comparing the magnitude of the macroscopic 
currents in oocytes expressing either wild type or mutant re- 
ce:3tors revealed no significant differences. The current re- 
sponses evoked by 1 btM ACh ranged between 1.65 + 1.26 
g;~ (n=13) for the wild type and 1.83+ 1.99 p.A (n=12) for 
th ~" mutant receptor eflecting on the fact that the quantitative 
c~mparison of currents evoked by bath-applied agonist in 
wlole cells displays a large variability. Fig. 2A shows, how- 
m er, that the agonist-evoked current response of the 
c~-sS248FI32 nAChR differs from the current response ob- 
sewed for the c~4132 nAChR. At 1 gM ACh the initial re- 
sponse of the mutant receptor decreased by more than 85% 
wthin 1 min, while the decrease of the current response of the 
w ld type receptor was much slower. Moreover, 2 min after 
tt~e first application of ACh to the mutant receptor, followed 
b a wash step with Mg2+-frog Ringer, the response to the 
sc:ond application of ACh at the same concentration was 
d, pressed by approximately 25%, whereas repetitive activation 
o the wild type receptor evoked comparable initial current 
amplitudes. These findings suggested that the c~4S248F[~2 re- 
ceptor may become inactivated or desensitized upon interac- 
ti, m with agonist at a significantly faster rate than the wild 
t3pe receptor. The different desensitization rates were esti- 
mated by a monoexponential fit to the time course for the 
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reduction of the current amplitude during application of 0.3, 
1 and 3 gM ACh concentrations (Fig. 2B). At 0.3 p.M ACh 
desensitization for the wild type receptor was very slow 
(tl/2= 147+71 s; n=4)  in contrast to the mutant receptor 
which showed already significant desensitization (t l /2--10+4 
s; n= 18). Between 0.3 and 1 p.M ACh the current hrough the 
mutant receptor inactivated ->10 times faster than that of the 
wild type receptor. The increased rate constants observed at 
3 btM and higher ACh concentrations (not shown), which are 
still significantly higher for the mutant receptor, indicate that 
both receptor subtypes how agonist-dependent desensitiza- 
tion which precludes an exact determination of dose-response 
relationships. 
3.2. The mutant and the wild type receptor recover at different 
rates from desensitization 
The traces shown in Fig. 2A gave a first indication of the 
difference in the rate of recovery from desensitization between 
the wild type and the mutant receptor. The time course of 
recovery Tp was analyzed by applying pairs of 5 s pulses of 
1 btM ACh with varying interpulse intervals (Fig. 3). The 
concentration of 1 gM ACh was chosen since the wild type 
receptor showed moderate desensitization at this concentra- 
tion, while desensitization of the mutant receptor was still 
slow enough to be measured. The interpulse intervals were 
varied between 10 and 120 s. With pauses shorter than 10 s 
no clear distinction between the first and the second pulse 
could be seen, perhaps due to the size and shape of Xenopus 
oocytes, which make a more rapid agonist application diffi- 
cult. To minimize a desensitizing effect of the preceding dou- 
ble pulse on the following response to agonist application, 
cells were washed with Mg2+-frog Ringer for 5 min to allow 
for complete recovery of the receptors. Fig. 3 shows that with 
30 s pulse intervals the wild type receptor esponds to both 
agonist pulses with a similar current amplitude displaying 
little or no desensitization. I  case of the c~4S248F[32 receptor 
the response to the second ACh pulse was reduced by ap- 
proximately 60%. With a pulse interval of 120 s the second 
agonist pulse could evoke a current amplitude reaching about 
90% of the amplitude of the current evoked by the first pulse. 
The presented ata fitted an exponential function giving time 
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Fig. 3. Effect of the mutation on the time course of recovery from 
desensitization. Pairs of 5 s pulses of 1 /aM ACh were applied to 
oocytes expressing wild type (O) or o~4S248FI32 nAChRs (©) with 
varying interpulse intervals. The maximal amplitude of the response 
to the second pulse is divided by that of the response to the first 
pulse and plotted against he interval between the two pulses. Each 
point shows the mean + half S.D. of the normalized responses of 5- 
15 oocytes from 2 3 separate sets of oocytes. 
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Fig. 4. Dose-response curves for oocytes with wild type (O) and 
a4S248Fl~2 (©) nAChRs for ACh in the range of 0.1 30 gM. Re- 
sponses were normalized to the response of the same oocyte to 30 
gM ACh and plotted against he logarithm of the ACh concentra- 
tion. Each point represents he average +S.D. of the normalized re- 
sponses of 15-21 oocytes from 2-3 donors. The plots were fitted to 
the Hill equation assuming a Hill coefficient of 1 to give apparent 
ECs0 values of 4.8 gM for the wild type and 2.1 gM for the 
c~4S248FI32 nAChR. 
constants for recovery of 6.4 s for the wild type and 58.8 s for 
the mutant receptor. 
3.3. The mutation does not alter the apparent affinity for ACh 
Effects due to mutations in the TM2 segment at positions 
6', 9' and 13' of the chicken ~7 neuronal nAChR [22,32,33] 
and positions 9' and 10' of the mouse muscle nAChR 
[23,34,35] on desensitization kinetics have been reported to 
be accompanied by changes in the apparent affinity for ago- 
nist as compared to wild type receptors. It was therefore of 
interest to investigate whether the altered desensitization 
properties of the a4S248F132 receptor, mutated at the 6' posi- 
tion, were due to an increased affinity for ACh (Fig. 4). The 
rapid, extensive desensitization f the human a4132 nAChR at 
high ACh concentrations, which is even more pronounced for 
the c~4S248F132 mutant receptor, makes the determination of
the true peak current amplitude difficult and for this reason it 
was not possible to normalize data to the maximal response 
values. Thus, dose-response curves were constructed by nor- 
malizing all current response measurements o the response 
evoked by 30/aM, the highest concentration at which reliable 
standard values could be obtained. Even more pronounced 
desensitization was observed by Luetje and Patrick [24] for 
the rat c~4132 nAChR and current responses were normalized 
to the response voked by 1 /aM ACh in this case to generate 
dose-response curves. The agonist-induced activation of both 
the a4132 and the c~4S248F132 nAChR was best fitted assuming 
a Hill coefficient of 1, a value which agrees with the observa- 
tion that neuronal nAChRs are characterized by Hill coeffi- 
cients of about 1.5 [1]. According to the dose-response curves 
generated for the two recombinant receptor subtypes there 
was no significant difference between the ECs0 value of the 
~4132 (4.8/aM) and the mutant a4S248F132 nAChR (2.1 gM). 
4. Discussion 
In the present study we have expressed recombinant euro- 
nal nAChRs composed of c~4132 subunits and mutated recep- 
tors containing c~4S248F subunits in order to investigate func- 
tional differences with regard to agonist affinity and 
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desensitization properties. Until now, the human c~4132 recep- 
tor has not been characterized in the oocyte expression sys- 
tem. Recently, the pharmacological properties of the human 
a4132 receptor have been studied in human embryonic kidney 
293 cells. The observed ECs0 of ACh for cation efltux stimu- 
lation was 44 gM, which differs from the electrophysiologi- 
cally determined EC~0 value of 4.8 gM by a factor 9. Further- 
more, desensitization was not pronounced and was only 
observed at much higher ACh concentrations [36]. This dif- 
ference could be due to the different expression systems and 
assay methods used. For instance, the chicken c~4132 nAChR 
expressed in fibroblasts appears to have a lower time constant 
of desensitization and a 10-fold higher ECs0 value than the 
receptor expressed in oocytes [37 39]. The ECs0 values of 
recombinant rat and chicken c~4132 receptors determined in 
oocytes were 2 ~tM and 0.77 gM [24,39], respectively, and 
are in the same order of magnitude as the ECs0 value deter- 
mined for the wild type human a4132 nAChR in the present 
study. The chicken receptor desensitized far more slowly than 
the human receptor whereas the desensitization of the rat 
receptor was even more pronounced [24,37]. These distinct 
properties could be caused by species differences: the TM2 
segment of the human a4 subunit differs at one amino acid 
position (1') from the rat c~4 subunit, and the human 132 sub- 
unit shows differences at three positions (3'/9'/16') compared 
with both the chicken and the rat 132 subunit. 
The substitution of serine at position 6' of the TM2 seg- 
ment by phenylalanine increased the rate of inactivation or 
desensitization a d prolonged significantly the time the recep- 
tor needed to recover to a conducting state. One could spec- 
ulate that the wild type and the mutant receptor are activated 
initially with comparable fficiency. The hydrophobic phenyl- 
alanines, however, replacing the hydrophilic serines may in- 
teract with each other or additional nearby located hydropho- 
bic side chains to reduce the water space. As a consequence a 
non-conducting state may be preferentially stabilized leading 
to the blockade of ion translocation and reducing the rate of 
recovery. Leonard et al. [21] proposed that serines at the IPS 
could be necessary for the stabilization of the open channel 
because of interactions between their OH-groups and water 
molecules either contacting other water molecules or hydrat- 
ing a permeant ion. Thus, the removal of serines at this posi- 
tion could affect he stability of the open configuration leading 
to changes in gating kinetics. Mutation of threonine at the 
homologous position in the chicken a7 subunit o the strongly 
polar glutamine and aspartate led to a deceleration of desen- 
sitization [22]. Upon replacement of the leucine at position 9' 
in the chicken c~7 receptor the velocity of desensitization de- 
creased with the size and hydrophobicity of the introduced 
residue with the most pronounced effect being caused by the 
introduction of serine [32]. In the serotonin 5-HT3 receptor, 
which is similar to the neuronal nAChR, hydrophobic substi- 
tution at position 9' in the TM2 segment accelerated desensi- 
tization, whereas the introduction of the polar threonine at 
the same position led to a marked reduction of desensitization 
[40]. Taken together, these results support the view that the 
residues located within the TM2 segment contribute to the 
stabilization of different channel configurations [10]. Depend- 
ing on their polarity and size they increase or decrease rates of 
desensitization both of several neuronal nAChRs and of the 
5-HT3 receptor and thus influence desensitization properties. 
For the Drosophila GABA receptor, carrying an alanine to 
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serme mutation at position 2' of the TM2 segment, it was 
shown that the markedly decreased esensitization was caused 
by a 5-fold stabilization of the channel open state and a 29- 
fold destabilization of the desensitized conformation [41]. 
Similarly, the leucine to threonine and leucine to serine muta- 
tions at position 9' of the mouse muscle receptor have been 
fotnd to lead to stabilization of the open state and a reduced 
sta ~ility of the closed state, respectively, accompanied by a 
deLreased esensitization [34,35]. 
"he great differences between the wild type c~4132 and the 
mt tant c~4S248FI32 nAChR concerning desensitization prop- 
ertes contrast with the almost identical dose-response r la- 
tiols. Effects on desensitization properties due to amino 
ac~ t substitutions in the TM2 segment without changes of 
tht apparent affinity for agonist have also been reported for 
tht Drosophila GABA receptor and the mouse 5-HT3 receptor 
[4(i,41]. In contrast, the mouse muscle nAChR with the serine 
to 9henylalanine mutation at the IPS exhibited an 8-fold high- 
er ~ensitivity to ACh as compared to the wild type receptor, 
without changes in desensitization properties [23]. Recently, 
Ferman and Yellen have suggested that the mutation could 
ha ,e a similar effect on the neuronal nAChR and lead to 
hy ~eractivity of the c~4S248F[32 nAChR [42]. This could not 
be confirmed by our results. The ->10-fold accelerated esen- 
sitization and strongly delayed recovery of the mutant recep- 
to~ lead to hypoactivity rather than to hyperactivity. Muscle 
an t neuronal nAChRs have been shown to differ in their 
ph trmacological and kinetic properties [25], suggesting that 
ap ~arently modest differences between the primary structure 
of distinct receptor types may lead to profound differences in 
th~ ir behavior. 
l'aken together, our results indicate that the reported muta- 
ti~a in the TM2 segment of the nAChR c~4 subunit causes 
se~ rares in ADNFLE patients by diminishing its activity: the 
ret eptor converts faster to a state in which it is unresponsive 
to ACh than the wild type receptor and remains longer in this 
co iformation. It has been hypothesized that the predominant 
roe of the nAChR in the brain could be that of a modifier of 
ne lronal excitability [43]. The Ser24Sphe mutation possibly 
db turbs the balance between inhibitory and excitatory synap- 
tic transmission, thus lowering the seizure threshold. It re- 
m, ins to be investigated why this epileptogenic effect is re- 
stricted to the frontal lobe and shows a striking dependence 
or the brain state of vigilance. 
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